The future of prescription drug reimbursement

The goal of this panel is to present to the ASHEcon community what payers and pharmaceutical companies are doing to innovate on prescription drug reimbursement currently and new opportunities with great promise to further increase affordability and access to appropriate care. Organizers: Rena Conti (Questrom School of Business, BU MPPL), Jon Gruber (MIT, economics) Structure of the panel: First, practitioners will present the economic rationale and implementation status of innovative reimbursement models. This will include a presentation on the LA Hep C subscription model (Rena Conti), drug mortgages and other innovative financing methods (Andy Lo), and other innovative models (VBID, Mike Chernew). Second, invited panelists will then comment on the economic rationales, implementation opportunities and challenges, roles for policy reform and likely outcomes posed by these models. Third, Rena will moderate questions from the audience to all participants. The goal of this section will be to define for the ASHecon audience key research questions left unexplored in these models currently and opportunities for program evaluation and other thinking about economic rationales and impacts on health, wealth and equity.